Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 9c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.52), $0.09 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $86 thousand versus the consensus estimate of $8.33 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• Nomura/Instinet Upgrades SK Innovation Co Ltd (096770:KS) to Neutral